{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:19:10Z","timestamp":1781061550352,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106258","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:55:12Z","timestamp":1775037312000},"source":"Crossref","is-referenced-by-count":1,"title":["The Past, Present, and Future of Dyslipidemia: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Prabhash C","family":"Manoria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong B","year":"2025","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al.. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025, 32:1001-15. 10.1093\/eurjpc\/zwae281","journal-title":"Eur J Prev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73786","article-title":"The rising burden of cardiovascular disease and thrombosis in India: an epidemiological review","volume":"16","author":"Loitongbam L","year":"2024","unstructured":"Loitongbam L, Surin WR. The rising burden of cardiovascular disease and thrombosis in India: an epidemiological review. Cureus. 2024, 16:e73786. 10.7759\/cureus.73786","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2019.08.002","article-title":"Atherosclerostic cardiovascular disease risk score: are Indians underestimating the risk of cardiovascular disease?","volume":"71","author":"Kumar A","year":"2019","unstructured":"Kumar A, Shariff M. Atherosclerostic cardiovascular disease risk score: are Indians underestimating the risk of cardiovascular disease?. Indian Heart J. 2019, 71:364-5. 10.1016\/j.ihj.2019.08.002","journal-title":"Indian Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14420","article-title":"Chronic kidney disease prevalence in India: a systematic review and meta-analysis from community-based representative evidence between 2011 to 2023","volume":"30","author":"Talukdar R","year":"2025","unstructured":"Talukdar R, Ajayan R, Gupta S, et al.. Chronic kidney disease prevalence in India: a systematic review and meta-analysis from community-based representative evidence between 2011 to 2023. Nephrology (Carlton). 2025, 30:e14420. 10.1111\/nep.14420","journal-title":"Nephrology (Carlton)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010075","article-title":"Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia","volume":"24","author":"Gaggini M","year":"2022","unstructured":"Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia. Int J Mol Sci. 2022, 24:10075. 10.3390\/ijms24010075","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.11648\/j.ajim.20200806.16","article-title":"Dyslipidemia and atherosclerotic cardiovascular disease: flash back and vision ahead","volume":"8","author":"Manoria PC","year":"2020","unstructured":"Manoria PC, Manoria P, Shrivastava RK, Parashar SK. Dyslipidemia and atherosclerotic cardiovascular disease: flash back and vision ahead. Am J Intern Med. 2020, 8:274-8. 10.11648\/j.ajim.20200806.16","journal-title":"Am J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.17816\/PAVLOVJ636812","article-title":"Place of lipid theory in history of study of atherosclerosis","volume":"32","author":"Kotlyarov SN","year":"2024","unstructured":"Kotlyarov SN. Place of lipid theory in history of study of atherosclerosis. Russian Medical Biological Herald. 2024, 32:681-9. 10.17816\/PAVLOVJ636812","journal-title":"Russian Medical Biological Herald"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1485801","article-title":"Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins","volume":"16","author":"Araujo G","year":"2025","unstructured":"Araujo G, Valencia LM, Martin-Ozimek A, Soto Y, Proctor SD. Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins. Front Immunol. 2025, 16:1485801. 10.3389\/fimmu.2025.1485801","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF03086236","article-title":"A historical perspective towards a non-invasive treatment for patients with atherosclerosis","volume":"17","author":"Slijkhuis W","year":"2009","unstructured":"Slijkhuis W, Mali W, Appelman Y. A historical perspective towards a non-invasive treatment for patients with atherosclerosis. Neth Heart J. 2009, 17:140-4. 10.1007\/BF03086236","journal-title":"Neth Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245897","article-title":"Modification of high-density lipoprotein functions by diet and other lifestyle changes: a systematic review of randomized controlled trials","volume":"10","author":"Sanllorente A","year":"2021","unstructured":"Sanllorente A, Lassale C, Soria-Florido MT, Casta\u00f1er O, Fit\u00f3 M, Hern\u00e1ez \u00c1. Modification of high-density lipoprotein functions by diet and other lifestyle changes: a systematic review of randomized controlled trials. J Clin Med. 2021, 10:5897. 10.3390\/jcm10245897","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111545","article-title":"Diversity of lipid function in atherogenesis: a focus on endothelial mechanobiology","volume":"22","author":"Kotlyarov S","year":"2021","unstructured":"Kotlyarov S. Diversity of lipid function in atherogenesis: a focus on endothelial mechanobiology. Int J Mol Sci. 2021, 22:1545. 10.3390\/ijms222111545","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/011573403X272750240109052319","article-title":"The role of triglycerides in atherosclerosis: recent pathophysiologic insights and therapeutic implications","volume":"20","author":"Akivis Y","year":"2024","unstructured":"Akivis Y, Alkaissi H, McFarlane SI, Bukharovich I. The role of triglycerides in atherosclerosis: recent pathophysiologic insights and therapeutic implications. Curr Cardiol Rev. 2024, 20:39-49. 10.2174\/011573403X272750240109052319","journal-title":"Curr Cardiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV","volume":"18","author":"Puri R","year":"2024","unstructured":"Puri R, Bansal M, Mehta V, et al.. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV. J Clin Lipidol. 2024, 18:e351-73. 10.1016\/j.jacl.2024.01.006","journal-title":"J Clin Lipidol"},{"key":"ref14","unstructured":"QRISK\u00ae3-lifetime cardiovascular risk calculator. (2018). https.\/\/www.qrisk.org\/lifetime\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach F","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al.. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025, 46:4359-78. 10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.04.024","article-title":"Maturation of lipid management in the 2025 ACC\/AHA acute coronary syndrome guideline: what it is and what it might have been","volume":"85","author":"Brandts J","year":"2025","unstructured":"Brandts J, Ray KK. Maturation of lipid management in the 2025 ACC\/AHA acute coronary syndrome guideline: what it is and what it might have been. J Am Coll Cardiol. 2025, 85:2107-10. 10.1016\/j.jacc.2025.04.024","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel SB","year":"2025","unstructured":"Patel SB, Wyne KL, Afreen S, et al.. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025, 31:236-62. 10.1016\/j.eprac.2024.09.016","journal-title":"Endocr Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22147","article-title":"Landmark lipid-lowering trials in the primary prevention of cardiovascular disease","volume":"36","author":"Chrispin J","year":"2013","unstructured":"Chrispin J, Martin SS, Hasan RK, et al.. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Clin Cardiol. 2013, 36:516-23. 10.1002\/clc.22147","journal-title":"Clin Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2024.02.003","article-title":"Lipid clinical trials with special reference to Indian population","volume":"76","author":"Basha A","year":"2024","unstructured":"Basha A, Ramakrishnan S. Lipid clinical trials with special reference to Indian population. Indian Heart J. 2024, 76:S130-7. 10.1016\/j.ihj.2024.02.003","journal-title":"Indian Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164716","article-title":"Current options and future perspectives in the treatment of dyslipidemia","volume":"11","author":"Muscoli S","year":"2022","unstructured":"Muscoli S, Ifrim M, Russo M, et al.. Current options and future perspectives in the treatment of dyslipidemia. J Clin Med. 2022, 11:4716. 10.3390\/jcm11164716","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81034","article-title":"Recent advances in the management of dyslipidemia: a systematic review","volume":"17","author":"Huang JX","year":"2025","unstructured":"Huang JX, Yousaf A, Moon J, Ahmed R, Uppal K, Pemminati S. Recent advances in the management of dyslipidemia: a systematic review. Cureus. 2025, 17:e81034. 10.7759\/cureus.81034","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101303","article-title":"Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials","volume":"24","author":"Ara\u00fajo B","year":"2025","unstructured":"Ara\u00fajo B, Arrighini GS, Queiroga F, et al.. Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials. Am J Prev Cardiol. 2025, 24:101303. 10.1016\/j.ajpc.2025.101303","journal-title":"Am J Prev Cardiol"},{"key":"ref23","unstructured":"Cardiovascular outcome study to evaluate the effect of Obicetrapib in patients with cardiovascular disease (PREVAIL). (2024). Accessed. February 09, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05202509."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho L","year":"2025","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG, et al.. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J. 2025, 287:1-9. 10.1016\/j.ahj.2025.03.019","journal-title":"Am Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/circ.152.suppl_3.4369873","article-title":"Abstract 4369873: LPA-targeted siRNAs lower Lp(a) by over 90%: a meta-analysis of olpasiran, lepodisiran, and zerlasiran","volume":"152","author":"Shokravi A","year":"2025","unstructured":"Shokravi A, Singh R, Sharma S, et al.. Abstract 4369873: LPA-targeted siRNAs lower Lp(a) by over 90%: a meta-analysis of olpasiran, lepodisiran, and zerlasiran. Circulation. 2025, 152:9873. 10.1161\/circ.152.suppl_3.4369873","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls SJ","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al.. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2025, 333:222-31. 10.1001\/jama.2024.24017","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad095","article-title":"First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA","volume":"10","author":"Lewis BS","year":"2024","unstructured":"Lewis BS. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA. Eur Heart J Cardiovasc Pharmacother. 2024, 10:87-8. 10.1093\/ehjcvp\/pvad095","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/467039-the-past-present-and-future-of-dyslipidemia-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:55:15Z","timestamp":1775037315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/467039-the-past-present-and-future-of-dyslipidemia-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.106258","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}